


PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)



Applicant's or agent's file reference 38107WOP00 AMM/ltn	FOR FURTHER ACTION		See Form PCT/IPEA/416
International application No. PCT/AU2004/000866	International filing date (day/month/year) 26 June 2004	Priority date (day/month/year) 26 June 2003	
International Patent Classification (IPC) or national classification and IPC Int. Cl. ⁷ C07C 279/22, C07D 241/24, A61K 31/155, A61P 31/12			
Applicant BIOTRON LIMITED et al			

1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 3 sheets, including this cover sheet.
3. This report is also accompanied by ANNEXES, comprising:
 - a. ☒ (sent to the applicant and to the International Bureau) a total of 79 sheets, as follows:
 - ☒ sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).
 - ☐ sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.
 - b. ☐ (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)) , containing a sequence listing and/or table related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).
4. This report contains indications relating to the following items:

<input checked="" type="checkbox"/>	Box No. I	Basis of the report
<input type="checkbox"/>	Box No. II	Priority
<input type="checkbox"/>	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
<input type="checkbox"/>	Box No. IV	Lack of unity of invention
<input checked="" type="checkbox"/>	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
<input type="checkbox"/>	Box No. VI	Certain documents cited
<input type="checkbox"/>	Box No. VII	Certain defects in the international application
<input type="checkbox"/>	Box No. VIII	Certain observations on the international application

Date of submission of the demand 26 April 2005	Date of completion of the report 8 June 2005
Name and mailing address of the IPEA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized Officer G. D. HEARDER Telephone No. (02) 6283 2553

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/AU2004/000866

Box No. I Basis of the report

1. With regard to the language, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.
- ☐ This report is based on translations from the original language into the following language which is the language of a translation furnished for the purposes of:
- ☐ international search (under Rules 12.3 and 23.1 (b))
- ☐ publication of the international application (under Rule 12.4)
- ☐ international preliminary examination (under Rules 55.2 and/or 55.3)
2. With regard to the elements of the international application, this report is based on (*replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report*):
- ☐ the international application as originally filed/furnished
- ☒ the description:
- pages 1-119 as originally filed/furnished
- pages* received by this Authority on with the letter of
- pages* received by this Authority on with the letter of
- ☒ the claims:
- pages as originally filed/furnished
- pages* as amended (together with any statement) under Article 19
- pages* 120-199 received by this Authority on 26 April 2005 with the letter of 26 April 2005
- pages* received by this Authority on with the letter of
- ☒ the drawings:
- pages 1/14-14/14 as originally filed/furnished
- pages* received by this Authority on with the letter of
- pages* received by this Authority on with the letter of
- ☐ a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.
3. ☐ The amendments have resulted in the cancellation of:
- ☐ the description, pages
- ☐ the claims, Nos.
- ☐ the drawings, sheets/figs
- ☐ the sequence listing (*specify*):
- ☐ any table(s) related to the sequence listing (*specify*):
4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).
- ☐ the description, pages
- ☐ the claims, Nos.
- ☐ the drawings, sheets/figs
- ☐ the sequence listing (*specify*):
- ☐ any table(s) related to the sequence listing (*specify*):

* If item 4 applies, some or all of those sheets may be marked "superseded."

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/AU2004/000866

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims 1-165	YES
	Claims	NO
Inventive step (IS)	Claims 1-165	YES
	Claims	NO
Industrial applicability (IA)	Claims 1-165	YES
	Claims	NO

2. Citations and explanations (Rule 70.7)

The following documents identified in the International Search Report have been considered for the purposes of this report:

- D1 US 4894376 A
- D2 DD 200618 A
- D3 The Merck Index, Twelfth Edition. Susan Budavari, Ed. Entry 426: Amiloride
- D4 BREDERECK H. et al. Chem. Ber. 1970, vol. 103, pages 245-255
- D5 DODD D. S. et al. Tetrahedron Lett. 2001, vol. 42, pages 1259-1262
- D6 ITO G. et al. Chem. Pharm. Bull. 1961, vol. 9, 245-248
- D7 FR 1435379
- D8 STN Database file CA, Abstract No. 67:100033
- D9 BODIPY® FL amiloride. Catalogue Number B-6905. Molecular Probes, Inc. 1999. [retrieved on 21-09-2004]. Retrieved from the Internet using The Way Back Machine (www.archive.org): <URL: <http://web.archive.org/web/19990831162814/http://www.probes.com/servlets/product?item=6905>>
- D10 WO 2003/063869


Claims 1-165

No individual citation or obvious combination of citations disclose the features of the claims

-120-


THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:-

1. An antiviral compound of Formula I




or pharmaceutically acceptable salts thereof,
wherein,


R₁ =



-121-



R_2 , R_3 and R_4 are independently hydrogen,



and wherein


10

X = hydrogen, hydroxy, nitro, halo, C_{1-6} alkyl, C_{1-6} alkyloxy, C_{3-6} cycloalkyl, halo-substituted C_{1-6} alkyl, halo-substituted C_{1-6} alkyloxy, phenyl, C_{1-6} alkenyl, C_{3-6} cycloalkenyl, C_{1-6} alkeneoxy, or benzo;

15

R_a , R_b , R_c , R_d , R_e , R_f , R_h , R_k , R_L , R_m , R_n , R_o , R_p independently = hydrogen, amino, halo, C_{1-5} alkyl, C_{1-5} alkyloxy, hydroxy, aryl, substituted aryl, substituted amino, mono or dialkyl-substituted amino, cycloalkyl-substituted amino, aryl-substituted amino,

-122-




or PrS;


R_g , R_i independently = hydrogen, hydroxy, halo, or C_{1-5} alkyl;

R_j = hydrogen, amino, halo, C_{1-5} alkyl, C_{1-5} alkyloxy, hydroxy, aryl, substituted aryl, substituted amino, alkyl-substituted amino, cycloalkyl-substituted amino, aryl-substituted amino, PrS,

5



and wherein



when R_1 is R_c , R_a and R_c are amino, and R_b is halo, R_2 , R_3 or R_4 cannot be hydrogen, benzyl or substituted benzyl or BODIPY-Fl;

10

when R_1 is $C_6H_5CH=CH$, R_2 is hydrogen and R_3 is phenyl, R_4 cannot be phenyl;

when R_1 is phenyl, R_2 is hydrogen, and R_3 is benzoyl, R_4 cannot be benzoyl;

15

when R_1 is phenyl, R_2 is substituted benzyl, R_3 is hydrogen and R_4 is hydrogen, R_n , R_o and R_p cannot all be hydrogen;

when R_1 is phenyl, R_3 is hydrogen and R_4 is hydrogen, R_2 cannot be benzyl or phenyl;

when R_1 is phenyl, R_2 is hydrogen, R_3 cannot be phenyl together with R_4 as benzoyl; and

20

when R_1 is phenyl, R_2 is hydrogen, R_3 and R_4 cannot both be benzyl.

2. A pharmaceutical composition comprising an antiviral compound according to claim 1 and optionally one or more pharmaceutical acceptable carriers or derivatives.

25

-123-

3. The pharmaceutical composition according to claim 3, further comprising one or more known antiviral compounds or molecules.
- 5 4. A method for reducing, retarding or otherwise inhibiting growth and/or replication of a virus comprising contacting a cell infected with said virus or exposed to said virus with a compound according to claim 1.
5. The method according to claim 4, wherein said virus is a Lentivirus.
- 10 6. The method according to claim 5, wherein said Lentivirus is Human Immunodeficiency Virus (HIV).
7. The method according to claim 6, wherein said compound is selected from the group consisting of :
 - (3-Chlorocinnamoyl)guanidine,
 - (3-Bromocinnamoyl)guanidine,
 - (2-Chlorocinnamoyl)guanidine,
 - (2-Bromocinnamoyl)guanidine,
 - 3-(trifluoromethyl)cinnamoylguanidine,
 - 5-bromo-2-fluorocinnamoylguanidine,
 - 3-methylcinnamoylguanidine,
 - 2-methylcinnamoylguanidine,
 - 2,3-dimethylcinnamoylguanidine,
 - Cinnamoylguanidine,
 - 6-methoxy-2-naphthoylguanidine,
 - trans-3-(1-naphthyl)acryloylguanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 2,6-dichlorocinnamoylguanidine,
 - 4-phenylbenzoylguanidine,
 - 2-ethylcinnamoylguanidine,
 - (4-Chlorocinnamoyl)guanidine,
 - 2-naphthoylguanidine,
 - 2,5-dimethylcinnamoylguanidine,
 - 3-isopropylcinnamoylguanidine hydrochloride,
 - (5-Phenyl-penta-2,4-dienoyl)guanidine,
 - 3-phenylcinnamoylguanidine,
 - (4-Bromocinnamoyl)guanidine,
 - 5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
 - 3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
 - 3-(trifluoromethoxy)cinnamoylguanidine,
 - 2-(trifluoromethyl)cinnamoylguanidine,

-124-

N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
2-ethoxycinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
(4-Methoxycinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
4-methylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
2-phenylcinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
3-t-butylcinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
3-fluorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-ethoxycinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
2'4 DichloroBenazamil HCl
2,3,5,6,-tetramethylcinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
2-(1-naphthyl)acetoyleguanidine,
2,3-difluorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
4-isopropylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
N-(cinnamoyl)-N'phenylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-(2-naphthyl)acetoyleguanidine,
(4-Hydroxycinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
N,N'-bis-(cinnamoyl)-N''-phenylguanidine,
(2-Furanacryloyl)guanidine,
Phenamil methanesulfonate salt ,
Benzamil hydrochloride,
(3-Nitrocinnamoyl)guanidine,
Benzyoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2-cyclohexylcinnamoylguanidine,
4-ethoxycinnamoylguanidine,
2,4-dichlorocinnamolyguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
N-amidino-3-amino-5-hexamethyleneimino-6-phenyl-
2-pyrazinecarboxamide,
(a-Methylcinnamoyl)guanidine,

-125-

cinnamoylguanidine hydrochloride,
[(4-Chlorophenoxy-acetyl]guanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-
pyrazinecarboxamide,
5-(4-fluorophenyl)amiloride,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
trans-3-Furanacryoylguanidine,
1-naphthoylguanidine,
5-tert-butylamino-amiloride,
3-methoxy -HMA,
(3-phenylpropanoyl)guanidine,
4-t-butylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
N,N'-Bis(3-phenylpropanoyl)guanidine,
N-Benzoyl-N'-cinnamoylguanidine and
1-bromo-2-naphthoylguanidine.

- 5
8. The method according to claim 6, wherein said compound is selected from the group consisting of 4-phenylbenzoylguanidine, (3-bromocinnamoyl)guanidine, 3-(trifluoromethyl)cinnamoylguanidine, 5-(N,N-hexamethylene)amiloride, and (5-Phenyl-penta-2,4-dienoyl)guanidine.
- 10
9. The method according to any one of claims 6 to 8, wherein said HIV is HIV-1.
10. The method according to claim 4 wherein said virus is a Coronavirus.
11. The method according to claim 10, wherein said Coronavirus is the Severe Acute Respiratory Syndrome virus (SARS).
- 15
12. The method according to claim 11, wherein said compound is selected from the group consisting of
- 2,3-difluorocinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,

-126-

(3-Chlorocinnamoyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2,5-dimethylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
4-isopropylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
6-methoxy-2-naphthoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
3-phenylcinnamoylguanidine,
(2-Chlorocinnamoyl)guanidine,
2'4 DichloroBenazamil HCl
4-phenylcinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
cinnamoylguanidine hydrochloride,
4-ethoxycinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
5-tert-butylamino-amiloride,
3-t-butylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
6-Iodoamiloride,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
(4-Hydroxycinnamoyl)guanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
(3-Nitrocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
2-(1-naphthyl)acetoyleguanidine,
2-ethylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-naphthoylguanidine,
5-(4-fluorophenyl)amiloride,
2-(trifluoromethyl)cinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,,
1-naphthoylguanidine,
Benzamil hydrochloride,
3-methoxy -HMA,
4-methylcinnamoylguanidine,
4-fluorocinnamoylguanidine,

-127-

3,4-(methylenedioxy)cinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
N-(cinnamoyl)-N'-phenylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3,5,6-tetramethylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Furanacryloyl)guanidine,
(3-phenylpropanoyl)guanidine,
2-(2-naphthyl)acetoylguanidine,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
4-phenylbenzoylguanidine,
2,4-dichlorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(Quinoline-2-carbonyl)guanidine,
(Phenylacetyl)guanidine,
N,N'-Bis(amidino)naphthalene-2,6-dicarboxamide,
6-bromo-2-naphthoylguanidine,
1-bromo-2-naphthoylguanidine,
2-chloro-6-fluorocinnamoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
Phenamil methanesulfonate salt,
N-Benzoyl-N'-cinnamoylguanidine and
N-(2-naphthoyl)-N'-phenylguanidine.

13. The method according to claim 11, wherein said compound is selected from the group consisting of cinnamoylguanidine, trans-3-(1-naphthyl)acryloylguanidine, and 6-methoxy-2-naphthoylguanidine.

14. The method according to claim 10, wherein said Coronavirus is human Coronavirus 229E.

15. The method according to claim 14, wherein said compound is selected from the group consisting of

-128-

4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
3-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
2,3-difluorocinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
2-phenylcinnamoylguanidine,
3-phenylcinnamoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
4-phenylbenzoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
4-(trifluoromethyl)cinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
1-naphthoylguanidine,
5-(4-fluorophenyl)amiloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(4-Chlorocinnamoyl)guanidine,
(3-Methoxycinnamoyl)guanidine,
5-bromo-2-fluorocinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,4,6-trimethylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(1-naphthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
2-ethoxycinnamoylguanidine,

-129-

3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
3-fluorocinnamoylguanidine,
cinnamoylguanidine hydrochloride,
2,3-dimethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-tert-butylamino-amiloride,
2-naphthoylguanidine,
N,N'-Bis(amidino)naphthalene-2,6-dicarboxamide,
N,N'-Bis(3-phenylpropanoyl)guanidine,
4-methylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
2,3,5,6-tetramethylcinnamoylguanidine,
3-ethoxycinnamoylguanidine,
N,N'-bis(3-phenylpropanoyl)-N"-phenylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(2-naphthyl)acetoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,

5-(2'-bromophenyl)penta-2,4-
dienoylguanidine,
(4-Bromocinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
(4-Methoxycinnamoyl)guanidine,
4-(trifluoromethyl)cinnamoylguanidine,
[(E)-3-(4-Dimethylaminophenyl)-2-
methylacryloyl]guanidine,
N-Benzoyl-N'-cinnamoylguanidine,
4-phenylbenzoylguanidine,
trans-3-Furanacryoylguanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-
Pyrzinecarboxamide,
N-(cinnamoyl)-N'phenylguanidine,
Cinnamoylguanidine,
3-methoxy-amiloride,
(3-phenylpropanoyl)guanidine,
3-methoxy-HMA,
Benzyoylguanidine,
N-amidino-3,5-diamino-6-phenyl-2-
Pyrzinecarboxamide,

-130-

(Quinoline-2-carbonyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
N-Cinnamoyl-N',N'-dimethylguanidine,
N-(2-naphthoyl)-N'-phenylguanidine and
(Phenylacetyl)guanidine.

16. The method according to claim 14, wherein said compound is selected from the group consisting of

2-t-butylcinnamoylguanidine,
4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
2-phenylcinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-phenylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
trans-3-(1-naphthyl)acryloylguanidine,
3-(2-naphthyl)acryloylguanidine,
2,4-dichlorocinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
4-methylcinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
(a-Methylcinnamoyl)guanidine,
2,3,5,6-tetramethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
3-t-butylcinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
3-methylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
(2-Bromocinnamoyl)guanidine,
3-ethoxycinnamoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-

-131-

Phenylguanidine,
2,4,6-trimethylcinnamoylguanidine,
2-methylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)-
guanidine,
(4-Phenoxybenzoyl)guanidine,
(2-Methoxycinnamoyl)guanidine,
Cinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
N,N'-Bis(amidino)naphthalene-2,6-
Dicarboxamide,
2,3-dimethylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
N,N'-Bis(3-phenylpropanoyl)guanidine,
2,3-difluorocinnamoylguanidine,
1-naphthoylguanidine,
6-methoxy-2-naphthoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-ethoxycinnamoylguanidine,
2-naphthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
(4-Hydroxycinnamoyl)guanidine,
5-(4-fluorophenyl)amiloride,
2-(1-naphthyl)acetoylguanidine,
(2-Furanacryloyl)guanidine,
N-Cinnamoyl-N',N'-dimethylguanidine,
2-(2-naphthyl)acetoylguanidine and
N,N'-bis(3phenylpropanoyl)-N"-
Phenylguanidine.

17. The method according to claim 10, wherein said Coronavirus is human Coronavirus OC43.

5

18. The method according to claim 17, wherein said compound is selected from the group consisting of

3-methylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
(3-Bromocinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,

-132-

4-isopropylcinnamoylguanidine,
Cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
2,4-dichlorocinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
(4-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-(trifluoromethoxy)cinnamoylguanidine and
2-t-butylcinnamoylguanidine.

19. The method according to claim 10, wherein said Coronavirus is porcine respiratory Coronavirus (PRCV).

5 20. The method according to claim 19, wherein said compound is selected from the group consisting of

5-(N,N-hexamethylene)amiloride,
6-methoxy-2-naphthoylguanidine,
Cinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
3-methylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
trans-3-(1-naphthyl)acryloylguanidine and
2-(2-naphthyl)acetoyleguanidine.

21. The method according to claim 10, wherein said Coronavirus is bovine Coronavirus (BCV).

10

22. The method according to claim 21, wherein said compound is selected from the group consisting of

(3-Bromocinnamoyl)guanidine,
3-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
5-(N,N-hexamethylene)amiloride,
trans-3-(1-naphthyl)acryloylguanidine,
Cinnamoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
2-(2-naphthyl)acetoyleguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,

-133-

N-(3-phenylpropanoyl)-N'-phenylguanidine and
4-phenylbenzoylguanidine.

23. The method according to claim 10, wherein said Coronavirus is any one of the known coronavirus isolates listed in Table 1.
- 5 24. The method according to claim 23, wherein said compound is selected from the group consisting of
- 4-isopropylcinnamoylguanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 3-(trifluoromethoxy)cinnamoylguanidine,
 - 4-t-butylcinnamoylguanidine,
 - 3-isopropylcinnamoylguanidine hydrochloride,
25. The method according to claim 4, wherein said virus is the Hepatitis C virus.
- 10 26. The method according to claim 25, wherein said compound is selected from the group consisting of
- 2,3-dimethylcinnamoylguanidine,
 - 2,4,6-trimethylcinnamoylguanidine,
 - 5-bromo-2-fluorocinnamoylguanidine,
 - (4-Bromocinnamoyl)guanidine,
 - 2,5-dimethylcinnamoylguanidine,
 - 3-(trifluoromethyl)cinnamoylguanidine,
 - 4-(trifluoromethyl)cinnamoylguanidine,
 - 6-methoxy-2-naphthoylguanidine,
 - (2-Chlorocinnamoyl)guanidine,
 - (4-Chlorocinnamoyl)guanidine,
 - (2-Bromocinnamoyl)guanidine,
 - 2,6-dichlorocinnamoylguanidine,
 - (3-Bromocinnamoyl)guanidine,
 - (3-Chlorocinnamoyl)guanidine,
 - 2-(trifluoromethyl)cinnamoylguanidine,
 - (4-Phenoxybenzoyl)guanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 4-isopropylcinnamoylguanidine,
 - trans-3-(1-naphthyl)acryloylguanidine,
 - 4-t-butylcinnamoylguanidine,
 - 2-t-butylcinnamoylguanidine,
 - 2-ethylcinnamoylguanidine,
 - 4-methylcinnamoylguanidine,

-134-

5-bromo-2-methoxycinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
1-naphthoylguanidine,
3-*t*-butylcinnamoylguanidine,
4-phenylbenzoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
N-(cinnamoyl)-N'-phenylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
Benzamil hydrochloride,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
3-(2-naphthyl)acryloylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2'4 DichloroBenazamil HCl,
5-*tert*-butylamino-amiloride,
5-(N-Ethyl-N-isopropyl)amiloride,
(4-Methoxycinnamoyl)guanidine,
4-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
3-ethoxycinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
4-phenylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(2-Furanacryloyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
5-(N,N-hexamethylene)amiloride,
2,3-difluorocinnamoylguanidine,
2-(1-naphthyl)acetoyleguanidine,
(α -Methylcinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
6-Iodoamiloride,
3,4-(methylenedioxy)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
Cinnamoylguanidine,
2-phenylcinnamoylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,
2-naphthoylguanidine,
3-phenylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
5-(4-fluorophenyl)amiloride,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,

-135-

5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
(3-phenylpropanoyl)guanidine,
2-chloro-6-fluorocinnamoylguanidine,
3-fluorocinnamoylguanidine,
2-methylcinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
1-bromo-2-naphthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
Phenamil methanesulfonate salt,
2,4-dichlorocinnamoylguanidine,
(4-Nitrocinnamoyl)guanidine,
3,4-difluorocinnamoylguanidine and
[(E)-3-(4-Dimethylaminophenyl)-2-
methylacryloyl]guanidine.

27. The method according to claim 4, wherein said virus is Equine Arteritis virus.
- 5 28. The method according to claim 27, wherein said compound is selected from the group consisting of
- 5-(N,N-hexamethylene)amiloride,
(3-Bromocinnamoyl)guanidine,
trans-3-(1-naphthyl)acryloylguanidine,
2-t-butylcinnamoylguanidine and
2-(cyclohex-1-en-1-yl)cinnamoylguanidine.
29. A method according to any one of claims 4 to 28, wherein said compound is provided as a pharmaceutical composition according to claim 2 or claim 3.
- 10 30. A method for preventing the infection of a cell exposed to a virus comprising contacting said cell with a compound according to claim 1.
- 15 31. The method according to claim 30, wherein said virus is a Lentivirus.
32. The method according to claim 31, wherein said Lentivirus is Human Immunodeficiency Virus (HIV).

33. The method according to claim 32, wherein said compound is selected from the group consisting of

(3-Chlorocinnamoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
3-(trifluoromethyl)cinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3-dimethylcinnamoylguanidine,
Cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
3,4-dichlorocinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
4-phenylbenzoylguanidine,
2-ethylcinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
2-naphthoylguanidine,
2,5-dimethylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-phenylcinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N"-phenylguanidine,
2-ethoxycinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
(4-Methoxycinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
4-methylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
2-phenylcinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
3-t-butylcinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
3-fluorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-ethoxycinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,

-137-

(2-Methoxycinnamoyl)guanidine,
2'4 DichloroBenazamil HCl,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
2-(1-naphthyl)acetoylguanidine,
2,3-difluorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
4-isopropylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
N-(cinnamoyl)-N'phenylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-(2-naphthyl)acetoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
N,N'-bis-(cinnamoyl)-N"-phenylguanidine,
(2-Furanacryloyl)guanidine,
Phenamil methanesulfonate salt ,
Benzamil hydrochloride,
(3-Nitrocinnamoyl)guanidine,
Benzyoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2-cyclohexylcinnamoylguanidine,
4-ethoxycinnamoylguanidine,
2,4-dichlorocinnamolyguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
N-amidino-3-amino-5-hexamethyleneimino-6-phenyl-
2-pyrazinecarboxamide,
(a-Methylcinnamoyl)guanidine,
cinnamoylguanidine hydrochloride,
[(4-Chlorophenoxy-acetyl]guanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-
pyrazinecarboxamide,
5-(4-fluorophenyl)amiloride,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
trans-3-Furanacryoylguanidine,
1-naphthoylguanidine,
5-tert-butylamino-amiloride,
3-methoxy -HMA,
(3-phenylpropanoyl)guanidine,
4-t-butylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
N,N'-Bis(3-phenylpropanoyl)guanidine,
N-Benzoyl-N'-cinnamoylguanidine and
1-bromo-2-naphthoylguanidine.

-138-

34. The method according to claim 32, wherein said compound is selected from the group consisting of 4-phenylbenzoylguanidine, (3-bromocinnamoyl)guanidine, 3-(trifluoromethyl)cinnamoylguanidine, 5-(N,N-hexamethylene)amiloride, and (5-Phenyl-penta-2,4-dienoyl)guanidine.
35. The method according to any one of claims 32 to 34, wherein said HIV is HIV-1.
36. The method according to claim 30 wherein said virus is a Coronavirus.
37. The method according to claim 36, wherein said Coronavirus is the Severe Acute Respiratory Syndrome virus (SARS).
38. The method according to claim 37, wherein said compound is selected from the group consisting of
- 2,3-difluorocinnamoylguanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 4-t-butylcinnamoylguanidine,
 - 3-(2-naphthyl)acryloylguanidine,
 - (3-Chlorocinnamoyl)guanidine,
 - 2'4 DichloroBenazamil HCl,
 - 3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
 - 2,5-dimethylcinnamoylguanidine,
 - trans-3-(1-naphthyl)acryloylguanidine,
 - 4-isopropylcinnamoylguanidine,
 - (3-Bromocinnamoyl)guanidine,
 - 6-methoxy-2-naphthoylguanidine,
 - 5-(N-Methyl-N-isobutyl)amiloride,
 - 3-phenylcinnamoylguanidine,
 - (2-Chlorocinnamoyl)guanidine,
 - 4-phenylcinnamoylguanidine,
 - 4-(trifluoromethyl)cinnamoylguanidine,
 - 3-(trifluoromethoxy)cinnamoylguanidine,
 - 3-(trifluoromethyl)cinnamoylguanidine,
 - 2-ethoxycinnamoylguanidine,
 - cinnamoylguanidine hydrochloride,
 - 4-ethoxycinnamoylguanidine,
 - (2-Bromocinnamoyl)guanidine,

-139-

2,6-dichlorocinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
5-tert-butylamino-amiloride,
3-t-butylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
6-Iodoamiloride,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
(4-Hydroxycinnamoyl)guanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
(3-Nitrocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
2-(1-naphthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-napthoylguanidine,
5-(4-fluorophenyl)amiloride,
2-(trifluoromethyl)cinnamoylguanidine,
N-(6-Hydroxy-2-napthoyl)-N'-phenylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,,
1-napthoylguanidine,
Benzamil hydrochloride,
3-methoxy -HMA,
4-methylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
N-(cinnamoyl)-N'phenylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Furanacryloyl)guanidine,
(3-phenylpropanoyl)guanidine,
2-(2-napthyl)acetoylguanidine,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
4-phenylbenzoylguanidine,
2,4-dichlorocinnamolyguanidine,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,

-140-

(4-Phenoxybenzoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(Quinoline-2-carbonyl)guanidine,
(Phenylacetyl)guanidine,
N,N'-Bis(amidino)napthalene-2,6-dicarboxamide,
6-bromo-2-naphthoylguanidine,
1-bromo-2-naphthoylguanidine,
2-chloro-6-fluorocinnamoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
Phenamil methanesulfonate salt,
N-Benzoyl-N'-cinnamoylguanidine and
N-(2-naphthoyl)-N'-phenylguanidine.

39. The method according to claim 37, wherein said compound is selected
from the group consisting of cinnamoylguanidine, trans-3-(1-
5 naphthyl)acryloylguanidine, and 6-methoxy-2-naphthoylguanidine.

40. The method according to claim 36, wherein said Coronavirus is human
Coronavirus 229E

10

41. The method according to claim 40, wherein said compound is selected
from the group consisting of

4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
3-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
2,3-difluorocinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
2-phenylcinnamoylguanidine,
3-phenylcinnamoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
4-phenylbenzoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,

-141-

(4-Phenoxybenzoyl)guanidine,
4-(trifluoromethyl)cinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
1-naphthoylguanidine,
5-(4-fluorophenyl)amiloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(4-Chlorocinnamoyl)guanidine,
(3-Methoxycinnamoyl)guanidine,
5-bromo-2-fluorocinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
(α -Methylcinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,4,6-trimethylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(1-naphthyl)acetoyleguanidine,
2-ethylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
2-ethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
3-fluorocinnamoylguanidine,
cinnamoylguanidine hydrochloride,
2,3-dimethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-tert-butylamino-amiloride,
2-naphthoylguanidine,
N,N'-Bis(amidino)naphthalene-2,6-dicarboxamide,
N,N'-Bis(3-phenylpropanoyl)guanidine,
4-methylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
2,3,5,6-tetramethylcinnamoylguanidine,
3-ethoxycinnamoylguanidine,

-142-

N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(2-naphthyl)acetoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,

5-(2'-bromophenyl)penta-2,4-
dienoylguanidine,
(4-Bromocinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
(4-Methoxycinnamoyl)guanidine,
4-(trifluoromethyl)cinnamoylguanidine,
[(E)-3-(4-Dimethylaminophenyl)-2-
methylacryloyl]guanidine,
N-Benzoyl-N'-cinnamoylguanidine,
4-phenylbenzoylguanidine,
trans-3-Furanacryoylguanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-
Pyrazinecarboxamide,
N-(cinnamoyl)-N''phenylguanidine,
Cinnamoylguanidine,
3-methoxy-amiloride,
(3-phenylpropanoyl)guanidine,
3-methoxy-HMA,
Benzyoylguanidine,
N-amidino-3,5-diamino-6-phynyl-2-
Pyrazinecarboxamide,
(Quinoline-2-carbonyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
N-Cinnamoyl-N',N'-dimethylguanidine,
N-(2-naphthoyl)-N'-phenylguanidine and
(Phenylacetyl)guanidine.

42. The method according to claim 40, wherein said compound is selected from the group consisting of

2-t-butylcinnamoylguanidine,
4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,

-143-

5-bromo-2-methoxycinnamoylguanidine,
2-phenylcinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-phenylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
trans-3-(1-naphthyl)acryloylguanidine,
3-(2-naphthyl)acryloylguanidine,
2,4-dichlorocinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
4-methylcinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
(a-Methylcinnamoyl)guanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
3-t-butylcinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
3-methylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
(2-Bromocinnamoyl)guanidine,
3-ethoxycinnamoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-
Phenylguanidine,
2,4,6-trimethylcinnamoylguanidine,
2-methylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)-
guanidine,
(4-Phenoxybenzoyl)guanidine,
(2-Methoxycinnamoyl)guanidine,
Cinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
N,N'-Bis(amidino)naphthalene-2,6-
Dicarboxamide,
2,3-dimethylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
N,N'-Bis(3-phenylpropanoyl)guanidine,
2,3-difluorocinnamoylguanidine,
1-naphthoylguanidine,

-144-

6-methoxy-2-naphthoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-ethoxycinnamoylguanidine,
2-naphthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
(4-Hydroxycinnamoyl)guanidine,
5-(4-fluorophenyl)amiloride,
2-(1-naphthyl)acetoylguanidine,
(2-Furanacryloyl)guanidine,
N-Cinnamoyl-N',N'-dimethylguanidine,
2-(2-naphthyl)acetoylguanidine and
N,N'-bis(3phenylpropanoyl)-N''-
Phenylguanidine.

43. The method according to claim 36, wherein said Coronavirus is human Coronavirus OC43.

5 44. The method according to claim 43, wherein said compound is selected from the group consisting of
3-methylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
(3-Bromocinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
4-isopropylcinnamoylguanidine,
Cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
2,4-dichlorocinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
(4-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-(trifluoromethoxy)cinnamoylguanidine and
2-t-butylcinnamoylguanidine.

-145-

45. The method according to claim 36, wherein said Coronavirus is porcine respiratory Coronavirus (PRCV).
46. The method according to claim 45, wherein said compound is selected from the group consisting of
- 5 5-(N,N-hexamethylene)amiloride,
6-methoxy-2-naphthoylguanidine,
Cinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
3-methylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
trans-3-(1-naphthyl)acryloylguanidine and
2-(2-naphthyl)acetoyleguanidine.
47. The method according to claim 36, wherein said Coronavirus is bovine Coronavirus (BCV).
- 10 48. The method according to claim 47, wherein said compound is selected from the group consisting of
- (3-Bromocinnamoyl)guanidine,
3-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
5-(N,N-hexamethylene)amiloride,
trans-3-(1-naphthyl)acryloylguanidine,
Cinnamoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
2-(2-naphthyl)acetoyleguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine and
4-phenylbenzoylguanidine.
49. The method according to claim 36, wherein said Coronavirus is any one of the known Coronavirus isolates listed in Table 1.
- 15 50. The method according to claim 49, wherein said compound is selected from the group consisting of
- 4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,

-146-

4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,

51. The method according to claim 30, wherein said virus is the Hepatitis C virus.
- 5 52. The method according to claim 51, wherein said compound is selected from the group consisting of
- 2,3-dimethylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(2-Chlorocinnamoyl)guanidine,
(4-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3,4-dichlorocinnamoylguanidine,
4-isopropylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
4-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
2-ethylcinnamoylguanidine,
4-methylcinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
1-naphthoylguanidine,
3-t-butylcinnamoylguanidine,
4-phenylbenzoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
N-(cinnamoyl)-N'-phenylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
Benzamil hydrochloride,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
N,N'-bis(3-phenylpropanoyl)-N''-phenylguanidine,
3-(2-naphthyl)acryloylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,

-147-

2'4 DichloroBenazamil HCl,
5-tert-butylamino-amiloride,
5-(N-Ethyl-N-isopropyl)amiloride,
(4-Methoxycinnamoyl)guanidine,
4-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
3-ethoxycinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
4-phenylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(2-Furanacryloyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
5-(N,N-hexamethylene)amiloride,
2,3-difluorocinnamoylguanidine,
2-(1-naphthyl)acetoyleguanidine,
(a-Methylcinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
6-Iodoamiloride,
3,4-(methylenedioxy)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
Cinnamoylguanidine,
2-phenylcinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-naphthoylguanidine,
3-phenylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
5-(4-fluorophenyl)amiloride,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
(3-phenylpropanoyl)guanidine,
2-chloro-6-fluorocinnamoylguanidine,
3-fluorocinnamoylguanidine,
2-methylcinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
1-bromo-2-naphthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
Phenamyl methanesulfonate salt,
2,4-dichlorocinnamolyguanidine,
(4-Nitrocinnamoyl)guanidine,

-148-

3,4-difluorocinnamoylguanidine and
[(E)-3-(4-Dimethylaminophenyl)-2-
methylacryloyl]guanidine.

53. The method according to claim 30, wherein said virus is the Equine
Arteritis virus.

5 54. The method according to claim 53, wherein said compound is selected
from the group consisting of

5-(N,N-hexamethylene)amiloride,
(3-Bromocinnamoyl)guanidine,
trans-3-(1-naphthyl)acryloylguanidine,
2-t-butylcinnamoylguanidine and
2-(cyclohex-1-en-1-yl)cinnamoylguanidine.

55. The method according to any one of claims 30 to 54, wherein said
compound is provided as a pharmaceutical composition according to claim
10 2 or claim 3.

56. A method for the therapeutic or prophylactic treatment of a subject
infected with or exposed to a virus, comprising the administration of a
compound according to claim 1 to a subject in need of said treatment.
15

57. The method according to claim 56, wherein said virus is a Lentivirus.

58. The method according to claim 57, wherein said Lentivirus is Human
Immunodeficiency Virus (HIV).
20

59. The method according to claim 58, wherein said compound is selected
from the group consisting of

(3-Chlorocinnamoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
3-(trifluoromethyl)cinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
3-methylcinnamoylguanidine,

-149-

2-methylcinnamoylguanidine,
2,3-dimethylcinnamoylguanidine,
Cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
3,4-dichlorocinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
4-phenylbenzoylguanidine,
2-ethylcinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
2-naphthoylguanidine,
2,5-dimethylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-phenylcinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N"-phenylguanidine,
2-ethoxycinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
(4-Methoxycinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
4-methylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
2-phenylcinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
3-t-butylcinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
3-fluorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-ethoxycinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
2'4 DichloroBenazamil HCl,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
2-(1-naphthyl)acetoyleguanidine,
2,3-difluorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
4-isopropylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
N-(cinnamoyl)-N'phenylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,

-150-

2-(2-naphthyl)acetoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
N,N'-bis-(cinnamoyl)-N''-phenylguanidine,
(2-Furanacryloyl)guanidine,
Phenamil methanesulfonate salt,
Benzamil hydrochloride,
(3-Nitrocinnamoyl)guanidine,
Benzyoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2-cyclohexylcinnamoylguanidine,
4-ethoxycinnamoylguanidine,
2,4-dichlorocinnamoylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
N-amidino-3-amino-5-hexamethyleneimino-6-phenyl-
2-pyrazinecarboxamide,
(a-Methylcinnamoyl)guanidine,
cinnamoylguanidine hydrochloride,
[(4-Chlorophenoxy-acetyl]guanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-
pyrazinecarboxamide,
5-(4-fluorophenyl)amiloride,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
trans-3-Furanacryoylguanidine,
1-naphthoylguanidine,
5-tert-butylamino-amiloride,
3-methoxy-HMA,
(3-phenylpropanoyl)guanidine,
4-t-butylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
N,N'-Bis(3-phenylpropanoyl)guanidine,
N-Benzoyl-N'-cinnamoylguanidine and
1-bromo-2-naphthoylguanidine.

60. The methods according to claim 58, wherein said compound is selected from the group consisting of 4-phenylbenzoylguanidine, (3-bromocinnamoyl)guanidine, 3-(trifluoromethyl)cinnamoylguanidine, 5-(N,N-hexamethylene)amiloride, and (5-Phenyl-penta-2,4-dienoyl)guanidine.

5

-151-

61. The method according to any one of claims 58 to 60, wherein said HIV is HIV-1.
62. The method according to claim 56 wherein said virus is a Coronavirus.
- 5 63. The method according to claim 62, wherein said Coronavirus is the Severe Acute Respiratory Syndrome virus (SARS).
- 10 64. The method according to claim 63, wherein said compound is selected from the group consisting of
- 2,3-difluorocinnamoylguanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 4-t-butylcinnamoylguanidine,
 - 3-(2-naphthyl)acryloylguanidine,
 - (3-Chlorocinnamoyl)guanidine,
 - 3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
 - 2,5-dimethylcinnamoylguanidine,
 - trans-3-(1-naphthyl)acryloylguanidine,
 - 4-isopropylcinnamoylguanidine,
 - (3-Bromocinnamoyl)guanidine,
 - 6-methoxy-2-naphthoylguanidine,
 - 5-(N-Methyl-N-isobutyl)amiloride,
 - 3-phenylcinnamoylguanidine,
 - (2-Chlorocinnamoyl)guanidine,
 - 2'4 DichloroBenazamil HCl,
 - 4-phenylcinnamoylguanidine,
 - 4-(trifluoromethyl)cinnamoylguanidine,
 - 3-(trifluoromethoxy)cinnamoylguanidine,
 - 3-(trifluoromethyl)cinnamoylguanidine,
 - 2-ethoxycinnamoylguanidine,
 - cinnamoylguanidine hydrochloride,
 - 4-ethoxycinnamoylguanidine,
 - (2-Bromocinnamoyl)guanidine,
 - 2,6-dichlorocinnamoylguanidine,
 - 3,4,5-trimethoxycinnamoylguanidine,
 - 5-tert-butylamino-amiloride,
 - 3-t-butylcinnamoylguanidine,
 - 5-bromo-2-fluorocinnamoylguanidine,
 - (4-Chlorocinnamoyl)guanidine,
 - 2-t-butylcinnamoylguanidine,
 - 2-cyclohexylcinnamoylguanidine,
 - 6-Iodoamiloride,
 - 3-(trans-hept-1-en-1-yl)cinnamoylguanidine,

-152-

(4-Bromocinnamoyl)guanidine,
(4-Hydroxycinnamoyl)guanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
(3-Nitrocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
2-(1-naphthyl)acetoyleguanidine,
2-ethylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-naphthoyleguanidine,
5-(4-fluorophenyl)amiloride,
2-(trifluoromethyl)cinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyle)-N'-phenylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,,
1-naphthoyleguanidine,
Benzamil hydrochloride,
3-methoxy -HMA,
4-methylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
N-(cinnamoyl)-N'phenylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Furanacryloyl)guanidine,
(3-phenylpropanoyl)guanidine,
2-(2-naphthyl)acetoyleguanidine,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
4-phenylbenzoylguanidine,
2,4-dichlorocinnamolyguanidine,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(Quinoline-2-carbonyl)guanidine,
(Phenylacetyl)guanidine,
N,N'-Bis(amidino)naphthalene-2,6-dicarboxamide,
6-bromo-2-naphthoyleguanidine,
1-bromo-2-naphthoyleguanidine,
2-chloro-6-fluorocinnamoylguanidine,

-153-

[(4-Chlorophenoxy-acetyl]guanidine,
Phenamil methanesulfonate salt,
N-Benzoyl-N'-cinnamoylguanidine and
N-(2-naphthoyl)-N'-phenylguanidine.

- 5
65. The method according to claim 63, wherein said compound is selected from the group consisting of cinnamoylguanidine, trans-3-(1-naphthyl)acryloylguanidine, and 6-methoxy-2-naphthoylguanidine.
66. The method according to claim 62, wherein said Coronavirus is human Coronavirus 229E.
- 10 67. The method according to claim 66, wherein said compound is selected from the group consisting of
- 4-isopropylcinnamoylguanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 3-(trifluoromethoxy)cinnamoylguanidine,
 - 4-t-butylcinnamoylguanidine,
 - 3-isopropylcinnamoylguanidine hydrochloride,
 - 3-t-butylcinnamoylguanidine,
 - 2-t-butylcinnamoylguanidine,
 - trans-3-(1-naphthyl)acryloylguanidine,
 - 5-bromo-2-methoxycinnamoylguanidine,
 - 2,3-difluorocinnamoylguanidine,
 - 3-(2-naphthyl)acryloylguanidine,
 - 2-phenylcinnamoylguanidine,
 - 3-phenylcinnamoylguanidine,
 - 3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
 - 4-phenylbenzoylguanidine,
 - 3-(trifluoromethyl)cinnamoylguanidine,
 - (4-Phenoxybenzoyl)guanidine,
 - 4-(trifluoromethyl)cinnamoylguanidine,
 - 2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
 - (4-Bromocinnamoyl)guanidine,
 - 5-(N,N-hexamethylene)amiloride,
 - 1-naphthoylguanidine,
 - 5-(4-fluorophenyl)amiloride,
 - (5-Phenyl-penta-2,4-dienoyl)guanidine,
 - (3-Bromocinnamoyl)guanidine,
 - 2,5-dimethylcinnamoylguanidine,
 - 2-(trifluoromethyl)cinnamoylguanidine,
 - 6-methoxy-2-naphthoylguanidine,

-154-

(4-Chlorocinnamoyl)guanidine,
(3-Methoxycinnamoyl)guanidine,
5-bromo-2-fluorocinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
(α -Methylcinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,4,6-trimethylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(1-naphthyl)acetoyleguanidine,
2-ethylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
2-ethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
3-fluorocinnamoylguanidine,
cinnamoylguanidine hydrochloride,
2,3-dimethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-tert-butylamino-amiloride,
2-naphthoylguanidine,
N,N'-Bis(amidino)naphthalene-2,6-dicarboxamide,
N,N'-Bis(3-phenylpropanoyl)guanidine,
4-methylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
2,3,5,6-tetramethylcinnamoylguanidine,
3-ethoxycinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(2-naphthyl)acetoyleguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,

5-(2'-bromophenyl)penta-2,4-
dienoylguanidine,
(4-Bromocinnamoyl)guanidine,

-155-

(2-Nitrocinnamoyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
(4-Methoxycinnamoyl)guanidine,
4-(trifluoromethyl)cinnamoylguanidine,
[(E)-3-(4-Dimethylaminophenyl)-2-methylacryloyl]guanidine,
N-Benzoyl-N'-cinnamoylguanidine,
4-phenylbenzoylguanidine,
trans-3-Furanacryoylguanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-Pyrazinecarboxamide,
N-(cinnamoyl)-N'-phenylguanidine,
Cinnamoylguanidine,
3-methoxy-amiloride,
(3-phenylpropanoyl)guanidine,
3-methoxy-HMA,
Benzyoylguanidine,
N-amidino-3,5-diamino-6-phenyl-2-Pyrazinecarboxamide,
(Quinoline-2-carbonyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
N-Cinnamoyl-N',N'-dimethylguanidine,
N-(2-naphthoyl)-N'-phenylguanidine and
(Phenylacetyl)guanidine.

68. The method according to claim 66, wherein said compound is selected from the group consisting of

2-t-butylcinnamoylguanidine,
4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
2-phenylcinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-phenylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
trans-3-(1-naphthyl)acryloylguanidine,
3-(2-naphthyl)acryloylguanidine,
2,4-dichlorocinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
4-methylcinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,

-156-

3-fluorocinnamoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
(a-Methylcinnamoyl)guanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
3-t-butylcinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
3-methylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
(2-Bromocinnamoyl)guanidine,
3-ethoxycinnamoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-
Phenylguanidine,
2,4,6-trimethylcinnamoylguanidine,
2-methylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)-
guanidine,
(4-Phenoxybenzoyl)guanidine,
(2-Methoxycinnamoyl)guanidine,
Cinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
N,N'-Bis(amidino)naphthalene-2,6-
Dicarboxamide,
2,3-dimethylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
N,N'-Bis(3-phenylpropanoyl)guanidine,
2,3-difluorocinnamoylguanidine,
1-naphthoylguanidine,
6-methoxy-2-naphthoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-ethoxycinnamoylguanidine,
2-naphthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
(4-Hydroxycinnamoyl)guanidine,
5-(4-fluorophenyl)amiloride,
2-(1-naphthyl)acetoylguanidine,
(2-Furanacryloyl)guanidine,
N-Cinnamoyl-N',N'-dimethylguanidine,
2-(2-naphthyl)acetoylguanidine and

-157-

N,N'-bis(3phenylpropanoyl)-N"-
Phenylguanidine.

69. The method according to claim 62, wherein said Coronavirus is human Coronavirus OC43.
- 5 70. The method according to claim 69, wherein said compound is selected from the group consisting of
3-methylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
(3-Bromocinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
4-isopropylcinnamoylguanidine,
Cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
2,4-dichlorocinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
(4-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-(trifluoromethoxy)cinnamoylguanidine and
2-t-butylcinnamoylguanidine.
71. The method according to claim 62, wherein said Coronavirus is porcine respiratory Coronavirus (PRCV).
- 10 72. The method according to claim 71, wherein said compound is selected from the group consisting of
5-(N,N-hexamethylene)amiloride,
6-methoxy-2-naphthoylguanidine,
Cinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
3-methylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
trans-3-(1-naphthyl)acryloylguanidine and

-158-

2-(2-naphthyl)acetoylguanidine.

73. The method according to claim 62, wherein said Coronavirus is bovine Coronavirus (BCV).
- 5 74. The method according to claim 73, wherein said compound is selected from the group consisting of
(3-Bromocinnamoyl)guanidine,
3-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
5-(N,N-hexamethylene)amiloride,
trans-3-(1-naphthyl)acryloylguanidine,
Cinnamoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
2-(2-naphthyl)acetoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine and
4-phenylbenzoylguanidine.
75. The method according to claim 62, wherein said Coronavirus is any one of the known Coronavirus isolates listed in Table 1.
- 10 76. The method according to claim 75, wherein said compound is selected from the group consisting of
4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
- 15 77. The method according to claim 56, wherein said virus is the Hepatitis C virus.
78. The method according to claim 77, wherein said compound is selected from the group consisting of
2,3-dimethylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,

-159-

2,5-dimethylcinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(2-Chlorocinnamoyl)guanidine,
(4-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3,4-dichlorocinnamoylguanidine,
4-isopropylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
4-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
2-ethylcinnamoylguanidine,
4-methylcinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
1-naphthoylguanidine,
3-t-butylcinnamoylguanidine,
4-phenylbenzoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
N-(cinnamoyl)-N'-phenylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
Benzamil hydrochloride,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
3-(2-naphthyl)acryloylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2'4 DichloroBenazamil HCl,
5-tert-butylamino-amiloride,
5-(N-Ethyl-N-isopropyl)amiloride,
(4-Methoxycinnamoyl)guanidine,
4-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
3-ethoxycinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
4-phenylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(2-Furanacryloyl)guanidine,

-160-

3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
5-(N,N-hexamethylene)amiloride,
2,3-difluorocinnamoylguanidine,
2-(1-naphthyl)acetoylguanidine,
(α -Methylcinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
6-Iodoamiloride,
3,4-(methylenedioxy)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
Cinnamoylguanidine,
2-phenylcinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-naphthoylguanidine,
3-phenylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
5-(4-fluorophenyl)amiloride,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
(3-phenylpropanoyl)guanidine,
2-chloro-6-fluorocinnamoylguanidine,
3-fluorocinnamoylguanidine,
2-methylcinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
1-bromo-2-naphthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
Phenamil methanesulfonate salt,
2,4-dichlorocinnamoylguanidine,
(4-Nitrocinnamoyl)guanidine,
3,4-difluorocinnamoylguanidine and
[(E)-3-(4-Dimethylaminophenyl)-2-
methylacryloyl]guanidine.

79. The method according to claim 56, wherein said virus is the Equine Arteritis virus.

5 80. The method according to claim 79, wherein said compound is selected from the group consisting of

5-(N,N-hexamethylene)amiloride,
(3-Bromocinnamoyl)guanidine,
trans-3-(1-naphthyl)acryloylguanidine,

-161-

2-t-butylcinnamoylguanidine and
2-(cyclohex-1-en-1-yl)cinnamoylguanidine.

81. The method according to any one of claims 56 to 80, wherein said compound is provided as a pharmaceutical composition according to claim 2 or claim 3.
- 5
82. A method of down regulating a membrane ion channel functional activity in a cell infected with a virus, comprising contacting said cell with a compound according to claim 1.
- 10
83. The method according to claim 82, wherein said virus is a Lentivirus.
84. The method according to claim 83, wherein said Lentivirus is Human Immunodeficiency Virus (HIV).
- 15
85. The method according to claim 84, wherein said membrane ion channel is the HIV Vpu membrane ion channel.
86. The method according to claim 85, wherein said compound is selected from the group consisting of
- (3-Chlorocinnamoyl)guanidine,
 - (3-Bromocinnamoyl)guanidine,
 - (2-Chlorocinnamoyl)guanidine,
 - (2-Bromocinnamoyl)guanidine,
 - 3-(trifluoromethyl)cinnamoylguanidine,
 - 5-bromo-2-fluorocinnamoylguanidine,
 - 3-methylcinnamoylguanidine,
 - 2-methylcinnamoylguanidine,
 - 2,3-dimethylcinnamoylguanidine,
 - Cinnamoylguanidine,
 - 6-methoxy-2-naphthoylguanidine,
 - trans-3-(1-naphthyl)acryloylguanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 2,6-dichlorocinnamoylguanidine,
 - 4-phenylbenzoylguanidine,
 - 2-ethylcinnamoylguanidine,
 - (4-Chlorocinnamoyl)guanidine,,
 - 2-naphthoylguanidine,

-162-

2,5-dimethylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-phenylcinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
2-ethoxycinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
(4-Methoxycinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
4-methylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
2-phenylcinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
3-t-butylcinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
3-fluorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-ethoxycinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
2'4 DichloroBenazamil HCl,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
2-(1-naphthyl)acetoyleguanidine,
2,3-difluorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
4-isopropylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
N-(cinnamoyl)-N'phenylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-(2-naphthyl)acetoyleguanidine,
(4-Hydroxycinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
N,N'-bis-(cinnamoyl)-N''-phenylguanidine,
(2-Furanacryloyl)guanidine,
Phenamil methanesulfonate salt ,
Benzamil hydrochloride,
(3-Nitrocinnamoyl)guanidine,
Benzyoylguanidine,
(4-Phenoxybenzoyl)guanidine,

-163-

3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2-cyclohexylcinnamoylguanidine,
4-ethoxycinnamoylguanidine,
2,4-dichlorocinnamoylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
N-amidino-3-amino-5-hexamethyleneimino-6-phenyl-
2-pyrazinecarboxamide,
(α -Methylcinnamoyl)guanidine,
cinnamoylguanidine hydrochloride,
[(4-Chlorophenoxy-acetyl]guanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-
pyrazinecarboxamide,
5-(4-fluorophenyl)amiloride,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
trans-3-Furanacryoylguanidine,
1-naphthoylguanidine,
5-tert-butylamino-amiloride,
3-methoxy -HMA,
(3-phenylpropanoyl)guanidine,
4-t-butylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
N,N'-Bis(3-phenylpropanoyl)guanidine,
N-Benzoyl-N'-cinnamoylguanidine and
1-bromo-2-naphthoylguanidine.

87. The method according to any one of claims 84 to 86, wherein said HIV is HIV-1.
- 5 88. The method according to claim 82, wherein said virus is a Coronavirus.
89. The method according to claim 88, wherein said membrane ion channel is the Coronavirus E protein.
- 10 90. The method according to claim 89, wherein said Coronavirus is the Severe Acute Respiratory Syndrome virus (SARS).
91. The method according to claim 90, wherein said compound is selected from the group consisting of
2,3-difluorocinnamoylguanidine,

-164-

3,4-dichlorocinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
(3-Chlorocinnamoyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2,5-dimethylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
4-isopropylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
6-methoxy-2-naphthoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
3-phenylcinnamoylguanidine,
(2-Chlorocinnamoyl)guanidine,
2'4 DichloroBenazamil HCl,
4-phenylcinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
cinnamoylguanidine hydrochloride,
4-ethoxycinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
5-tert-butylamino-amiloride,
3-t-butylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
6-Iodoamiloride,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
(4-Hydroxycinnamoyl)guanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine;
(3-Nitrocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
2-(1-naphthyl)acetoyleguanidine,
2-ethylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-naphthoylguanidine,
5-(4-fluorophenyl)amiloride,
2-(trifluoromethyl)cinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
1-naphthoylguanidine,
Benzamil hydrochloride,

-165-

3-methoxy-HMA,
4-methylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
N-(cinnamoyl)-N'-phenylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3,5,6-tetramethylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Furanacryloyl)guanidine,
(3-phenylpropanoyl)guanidine,
2-(2-naphthyl)acetoyleguanidine,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
4-phenylbenzoylguanidine,
2,4-dichlorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(Quinoline-2-carbonyl)guanidine,
(Phenylacetyl)guanidine,
N,N'-Bis(amidino)napthalene-2,6-dicarboxamide,
6-bromo-2-naphthoylguanidine,
1-bromo-2-naphthoylguanidine,
2-chloro-6-fluorocinnamoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
Phenamil methanesulfonate salt,
N-Benzoyl-N'-cinnamoylguanidine and
N-(2-naphthoyl)-N'-phenylguanidine.

92. The method according to claim 90, wherein said Coronavirus is human Coronavirus 229E.

5

93. The method according to claim 92, wherein said compound is selected from the group consisting of

4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,

-166-

3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
3-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
2,3-difluorocinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
2-phenylcinnamoylguanidine,
3-phenylcinnamoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
4-phenylbenzoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
4-(trifluoromethyl)cinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
1-naphthoylguanidine,
5-(4-fluorophenyl)amiloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(4-Chlorocinnamoyl)guanidine,
(3-Methoxycinnamoyl)guanidine,
5-bromo-2-fluorocinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,4,6-trimethylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(1-naphthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
2-ethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,

-167-

3-fluorocinnamoylguanidine,
cinnamoylguanidine hydrochloride,
2,3-dimethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-tert-butylamino-amiloride,
2-naphthoylguanidine,
N,N'-Bis(amidino)naphthalene-2,6-dicarboxamide,
N,N'-Bis(3-phenylpropanoyl)guanidine,
4-methylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-ethoxycinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N"-phenylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(2-naphthyl)acetoylguanidine and
N-(3-phenylpropanoyl)-N'-phenylguanidine.

94. The method according to claim 89, wherein said Coronavirus is any one of the known Coronavirus isolates listed in Table 1.

5

95. The method according to claim 94, wherein said compound is selected from the group consisting of

4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,

96. The method according to claim 82, wherein said virus is the Hepatitis C virus.

10

97. The method according to claim 96, wherein said membrane ion channel is the Hepatitis C virus p7 membrane ion channel.

-168-

98. The method according to claim 97, wherein said compound is selected from the group consisting of

2,3-dimethylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(2-Chlorocinnamoyl)guanidine,
(4-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3,4-dichlorocinnamoylguanidine,
4-isopropylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
4-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
2-ethylcinnamoylguanidine,
4-methylcinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
1-naphthoylguanidine,
3-t-butylcinnamoylguanidine,
4-phenylbenzoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
N-(cinnamoyl)-N'-phenylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
Benzamil hydrochloride,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
3-(2-naphthyl)acryloylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2'4 DichloroBenazamil HCl,
5-tert-butylamino-amiloride,
5-(N-Ethyl-N-isopropyl)amiloride,
(4-Methoxycinnamoyl)guanidine,
4-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,

-169-

(4-Hydroxycinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
3-ethoxycinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
4-phenylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(2-Furanacryloyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
5-(N,N-hexamethylene)amiloride,
2,3-difluorocinnamoylguanidine,
2-(1-naphthyl)acetoyleguanidine,
(a-Methylcinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
6-Iodoamiloride,
3,4-(methylenedioxy)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
Cinnamoylguanidine,
2-phenylcinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-naphthoylguanidine,
3-phenylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
5-(4-fluorophenyl)amiloride,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
(3-phenylpropanoyl)guanidine,
2-chloro-6-fluorocinnamoylguanidine,
3-fluorocinnamoylguanidine,
2-methylcinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
1-bromo-2-naphthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
Phenamil methanesulfonate salt,
2,4-dichlorocinnamoylguanidine,
(4-Nitrocinnamoyl)guanidine,
3,4-difluorocinnamoylguanidine and
[(E)-3-(4-Dimethylaminophenyl)-2-methylacryloyl]guanidine.

-170-

99. The method according to any one of claims 82 to 98, wherein said compound is provided as a pharmaceutical composition according to claim 2 or claim 3.
- 5 100. A method of reducing, retarding or otherwise inhibiting growth and/or replication of a virus that has infected a cell, said method comprising contacting said infected cell with a compound according to claim 1, wherein said compound down regulates functional activity of a membrane ion channel derived from said virus and expressed in said infected cell.
- 10 101. The method according to claim 100, wherein said virus is a Lentivirus.
102. The method according to claim 101, wherein said Lentivirus is Human Immunodeficiency Virus (HIV).
- 15 103. The method according to claim 102, wherein said membrane ion channel is the HIV Vpu membrane ion channel.
- 20 104. The method according to claim 103, wherein said compound is selected from the group consisting of
- (3-Chlorocinnamoyl)guanidine,
 - (3-Bromocinnamoyl)guanidine,
 - (2-Chlorocinnamoyl)guanidine,
 - (2-Bromocinnamoyl)guanidine,
 - 3-(trifluoromethyl)cinnamoylguanidine,
 - 5-bromo-2-fluorocinnamoylguanidine,
 - 3-methylcinnamoylguanidine,
 - 2-methylcinnamoylguanidine,
 - 2,3-dimethylcinnamoylguanidine,
 - Cinnamoylguanidine,
 - 6-methoxy-2-naphthoylguanidine,
 - trans-3-(1-naphthyl)acryloylguanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 2,6-dichlorocinnamoylguanidine,
 - 4-phenylbenzoylguanidine,
 - 2-ethylcinnamoylguanidine,
 - (4-Chlorocinnamoyl)guanidine,,
 - 2-naphthoylguanidine,

-171-

2,5-dimethylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-phenylcinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
2-ethoxycinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
(4-Methoxycinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
4-methylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
2-phenylcinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
3-t-butylcinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
3-fluorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-ethoxycinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
2'4 DichloroBenazamil HCl,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
2-(1-naphthyl)acetoyleguanidine,
2,3-difluorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
4-isopropylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
N-(cinnamoyl)-N'phenylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,
2-(2-naphthyl)acetoyleguanidine,
(4-Hydroxycinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
N,N'-bis-(cinnamoyl)-N''-phenylguanidine,
(2-Furanacryloyl)guanidine,
Phenamil methanesulfonate salt ,
Benzamil hydrochloride,
(3-Nitrocinnamoyl)guanidine,
Benzyoylguanidine,
(4-Phenoxybenzoyl)guanidine,

-172-

3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2-cyclohexylcinnamoylguanidine,
4-ethoxycinnamoylguanidine,
2,4-dichlorocinnamolyguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
N-amidino-3-amino-5-hexamethyleneimino-6-phenyl-
2-pyrazinecarboxamide,
(a-Methylcinnamoyl)guanidine,
cinnamoylguanidine hydrochloride,
[(4-Chlorophenoxy-acetyl]guanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-
pyrazinecarboxamide,
5-(4-fluorophenyl)amiloride,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
trans-3-Furanacryoylguanidine,
1-naphthoylguanidine,
5-tert-butylamino-amiloride,
3-methoxy -HMA,
(3-phenylpropanoyl)guanidine,
4-t-butylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
N,N'-Bis(3-phenylpropanoyl)guanidine,
N-Benzoyl-N'-cinnamoylguanidine and
1-bromo-2-naphthoylguanidine.

105. The method according to any one of claims 102 to 104, wherein said HIV
is HIV-1.

5

106. The method according to claim 100, wherein said virus is a Coronavirus.

107. The method according to claim 106, wherein said membrane ion channel
is the Coronavirus E protein.

10

108. The method according to claim 107, wherein said Coronavirus is the
Severe Acute Respiratory Syndrome virus (SARS).

109. The method according to claim 108, wherein said compound is selected
from the group consisting of

15

-173-

2,3-difluorocinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
(3-Chlorocinnamoyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2,5-dimethylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
4-isopropylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
6-methoxy-2-naphthoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
3-phenylcinnamoylguanidine,
(2-Chlorocinnamoyl)guanidine,
2'4 DichloroBenazamil HCl,
4-phenylcinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
cinnamoylguanidine hydrochloride,
4-ethoxycinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
5-tert-butylamino-amiloride,
3-t-butylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
6-Iodoamiloride,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
(4-Hydroxycinnamoyl)guanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
(3-Nitrocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
2-(1-naphthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-naphthoylguanidine,
5-(4-fluorophenyl)amiloride,
2-(trifluoromethyl)cinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
1-naphthoylguanidine,

-174-

Benzamil hydrochloride,
3-methoxy-HMA,
4-methylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
N-(cinnamoyl)-N'-phenylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3,5,6-tetramethylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Furanacryloyl)guanidine,
(3-phenylpropanoyl)guanidine,
2-(2-naphthyl)acetoyleguanidine,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
4-phenylbenzoylguanidine,
2,4-dichlorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(Quinoline-2-carbonyl)guanidine,
(Phenylacetyl)guanidine,
N,N'-Bis(amidino)naphthalene-2,6-dicarboxamide,
6-bromo-2-naphthoylguanidine,
1-bromo-2-naphthoylguanidine,
2-chloro-6-fluorocinnamoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
Phenamil methanesulfonate salt,
N-Benzoyl-N'-cinnamoylguanidine and
N-(2-naphthoyl)-N'-phenylguanidine.

110. The method according to claim 107, wherein said Coronavirus is human Coronavirus 229E.

5

111. The method according to claim 110, wherein said compound is selected from the group consisting of
4-isopropylcinnamoylguanidine,

-175-

3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
3-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
2,3-difluorocinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
2-phenylcinnamoylguanidine,
3-phenylcinnamoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
4-phenylbenzoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
4-(trifluoromethyl)cinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
1-naphthoylguanidine,
5-(4-fluorophenyl)amiloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(4-Chlorocinnamoyl)guanidine,
(3-Methoxycinnamoyl)guanidine,
5-bromo-2-fluorocinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,4,6-trimethylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(1-naphthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
2-ethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,

-176-

2-methylcinnamoylguanidine,
3-fluorocinnamoylguanidine,
cinnamoylguanidine hydrochloride,
2,3-dimethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-tert-butylamino-amiloride,
2-naphthoylguanidine,
N,N'-Bis(amidino)napthalene-2,6-dicarboxamide,
N,N'-Bis(3-phenylpropanoyl)guanidine,
4-methylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-ethoxycinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N"-phenylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(2-naphthyl)acetoylguanidine and
N-(3-phenylpropanoyl)-N'-phenylguanidine.

112. The method according to claim 107, wherein said Coronavirus is any one of the known Coronavirus isolates listed in Table 1.

5 113. The method according to claim 112, wherein said compound is selected from the group consisting of

4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,

114. The method according to claim 100, wherein said virus is the Hepatitis C virus.

10

115. The method according to claim 114, wherein said membrane ion channel is the Hepatitis C virus p7 membrane ion channel.

-177-

116. The method according to claim 115, wherein said compound is selected from the group consisting of

2,3-dimethylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(2-Chlorocinnamoyl)guanidine,
(4-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3,4-dichlorocinnamoylguanidine,
4-isopropylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
4-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
2-ethylcinnamoylguanidine,
4-methylcinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
1-naphthoylguanidine,
3-t-butylcinnamoylguanidine,
4-phenylbenzoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
N-(cinnamoyl)-N'-phenylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
N,N'-bis(3-phenylpropanoyl)-N''-phenylguanidine,
3-(2-naphthyl)acryloylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2'4 DichloroBenazamil HCl,
5-tert-butylamino-amiloride,
5-(N-Ethyl-N-isopropyl)amiloride,
(4-Methoxycinnamoyl)guanidine,
4-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,

-178-

3-ethoxycinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
4-phenylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(2-Furanacryloyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
5-(N,N-hexamethylene)amiloride,
2,3-difluorocinnamoylguanidine,
2-(1-naphthyl)acetoyleguanidine,
(a-Methylcinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
6-Iodoamiloride,
3,4-(methylenedioxy)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
Cinnamoylguanidine,
2-phenylcinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-naphthoylguanidine,
3-phenylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
5-(4-fluorophenyl)amiloride,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
(3-phenylpropanoyl)guanidine,
2-chloro-6-fluorocinnamoylguanidine,
3-fluorocinnamoylguanidine,
2-methylcinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
2'4 DichloroBenazamil HCl,
1-bromo-2-naphthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
Phenamil methanesulfonate salt,
2,4-dichlorocinnamoylguanidine,
(4-Nitrocinnamoyl)guanidine,
3,4-difluorocinnamoylguanidine and
[(E)-3-(4-Dimethylaminophenyl)-2-
methylacryloyl]guanidine.

117. The method according to any one of claims 100 to 116, wherein said compound is provided as a pharmaceutical composition according to claim 2 or claim 3.

-179-

118. A method of reducing, retarding or otherwise inhibiting growth and/or replication of a virus that has infected a cell in a mammal, said method comprising administering to said mammal a compound according claim 1,
5 wherein said compound down regulates functional activity of a membrane ion channel expressed in said infected cell.
119. The method according to claim 118, wherein said virus is a Lentivirus.
- 10 120. The method according to claim 119, wherein said Lentivirus is Human Immunodeficiency Virus (HIV).
121. The method according to claim 120, wherein said compound is selected from the group consisting of
- (3-Chlorocinnamoyl)guanidine,
 - (3-Bromocinnamoyl)guanidine,
 - (2-Chlorocinnamoyl)guanidine,
 - (2-Bromocinnamoyl)guanidine,
 - 3-(trifluoromethyl)cinnamoylguanidine,
 - 5-bromo-2-fluorocinnamoylguanidine,
 - 3-methylcinnamoylguanidine,
 - 2-methylcinnamoylguanidine,
 - 2,3-dimethylcinnamoylguanidine,
 - Cinnamoylguanidine,
 - 6-methoxy-2-naphthoylguanidine,
 - trans-3-(1-naphthyl)acryloylguanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 2,6-dichlorocinnamoylguanidine,
 - 4-phenylbenzoylguanidine,
 - 2-ethylcinnamoylguanidine,
 - (4-Chlorocinnamoyl)guanidine,,
 - 2-naphthoylguanidine,
 - 2,5-dimethylcinnamoylguanidine,
 - 3-isopropylcinnamoylguanidine hydrochloride,
 - (5-Phenyl-penta-2,4-dienoyl)guanidine,
 - 3-phenylcinnamoylguanidine,
 - (4-Bromocinnamoyl)guanidine,
 - 5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
 - 3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
 - 3-(trifluoromethoxy)cinnamoylguanidine,
 - 2-(trifluoromethyl)cinnamoylguanidine,

-180-

N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
2-ethoxycinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
(4-Methoxycinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
4-methylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
2-phenylcinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
3-t-butylcinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
3-fluorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-ethoxycinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
2-(1-naphthyl)acetoylguanidine,
2,3-difluorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
4-isopropylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
N-(cinnamoyl)-N'phenylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-(2-naphthyl)acetoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
N,N'-bis-(cinnamoyl)-N''-phenylguanidine,
(2-Furanacryloyl)guanidine,
Phenamil methanesulfonate salt ,
Benzamil hydrochloride,
(3-Nitrocinnamoyl)guanidine,
Benzyoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2-cyclohexylcinnamoylguanidine,
4-ethoxycinnamoylguanidine,
2,4-dichlorocinnamolyguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
N-amidino-3-amino-5-hexamethyleneimino-6-phenyl-
2-pyrazinecarboxamide,
(a-Methylcinnamoyl)guanidine,
cinnamoylguanidine hydrochloride,

-181-

[(4-Chlorophenoxy-acetyl]guanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-
pyrazinecarboxamide,
5-(4-fluorophenyl)amiloride,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
trans-3-Furanacryoylguanidine,
1-naphthoylguanidine,
5-tert-butylamino-amiloride,
3-methoxy -HMA,
(3-phenylpropanoyl)guanidine,
4-t-butylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
N,N'-Bis(3-phenylpropanoyl)guanidine,
N-Benzoyl-N'-cinnamoylguanidine and
1-bromo-2-naphthoylguanidine.

122. The method according to any one of claims 118 to 121, wherein said
membrane ion channel is the HIV Vpu membrane ion channel.
123. The method according to any one of claims 120 to 122, wherein said HIV
is HIV-1.
124. The method according to claim 118, wherein said virus is a Coronavirus.
125. The method according to claim 124, wherein said Coronavirus is the
Severe Acute Respiratory Syndrome virus (SARS).
126. The method according to claim 125, wherein said compound is selected
from the group consisting of
- 2,3-difluorocinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
(3-Chlorocinnamoyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2,5-dimethylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
4-isopropylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,

-182-

6-methoxy-2-naphthoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
3-phenylcinnamoylguanidine,
(2-Chlorocinnamoyl)guanidine,
2'4 DichloroBenazamil HCl,
4-phenylcinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
cinnamoylguanidine hydrochloride,
4-ethoxycinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
5-tert-butylamino-amiloride,
3-t-butylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
6-Iodoamiloride,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
(4-Hydroxycinnamoyl)guanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
(3-Nitrocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
2-(1-naphthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-naphthoylguanidine,
5-(4-fluorophenyl)amiloride,
2-(trifluoromethyl)cinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
1-naphthoylguanidine,
Benzamil hydrochloride,
3-methoxy -HMA,
4-methylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
N-(cinnamoyl)-N'phenylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,

-183-

2,3,5,6,-tetramethylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Furanacryloyl)guanidine,
(3-phenylpropanoyl)guanidine,
2-(2-naphthyl)acetoyleguanidine,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
4-phenylbenzoylguanidine,
2,4-dichlorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(Quinoline-2-carbonyl)guanidine,
(Phenylacetyl)guanidine,
N,N'-Bis(amidino)naphthalene-2,6-dicarboxamide,
6-bromo-2-naphthoylguanidine,
1-bromo-2-naphthoylguanidine,
2-chloro-6-fluorocinnamoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
Phenamil methanesulfonate salt ,
N-Benzoyl-N'-cinnamoylguanidine and
N-(2-naphthoyl)-N'-phenylguanidine.

127. The method according to any one of claim 124 or 126, wherein said
membrane ion channel is the Coronavirus E protein.

5

128. The method according to claim 124, wherein said Coronavirus is human
Coronavirus 229E.

129. The method according to claim 128, wherein said compound is selected
from the group consisting of

10

4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
3-t-butylcinnamoylguanidine,

-184-

2-t-butylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
2,3-difluorocinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
2-phenylcinnamoylguanidine,
3-phenylcinnamoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
4-phenylbenzoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
4-(trifluoromethyl)cinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
1-naphthoylguanidine,
5-(4-fluorophenyl)amiloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(4-Chlorocinnamoyl)guanidine,
(3-Methoxycinnamoyl)guanidine,
5-bromo-2-fluorocinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,4,6-trimethylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(1-naphthyl)acetoyleguanidine,
2-ethylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
2-ethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
3-fluorocinnamoylguanidine,
cinnamoylguanidine hydrochloride,
2,3-dimethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,

-185-

4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-tert-butylamino-amiloride,
2-naphthoylguanidine,
N,N'-Bis(amidino)naphthalene-2,6-dicarboxamide,
N,N'-Bis(3-phenylpropanoyl)guanidine,
4-methylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-ethoxycinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(2-naphthyl)acetoylguanidine and
N-(3-phenylpropanoyl)-N'-phenylguanidine.

130. The method according to any one of claims 128 or 129, wherein said membrane ion channel is the Coronavirus E protein.

5 131. The method according to claim 124, wherein said Coronavirus is any one of the known Coronavirus isolates listed in Table 1.

132. The method according to claim 131, wherein said compound is selected from the group consisting of

4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,

10

133. The method according to claim 131 or claim 132, wherein said membrane ion channel is the Coronavirus E protein.

134. The method according to claim 118, wherein said virus is the Hepatitis C virus.

15

-186-

135. The method according to claim 134, wherein said compound is selected from the group consisting of

2,3-dimethylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(2-Chlorocinnamoyl)guanidine,
(4-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3,4-dichlorocinnamoylguanidine,
4-isopropylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
4-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
2-ethylcinnamoylguanidine,
4-methylcinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
1-naphthoylguanidine,
3-t-butylcinnamoylguanidine,
4-phenylbenzoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
N-(cinnamoyl)-N'-phenylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
Benzamil hydrochloride,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
3-(2-naphthyl)acryloylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2'4 DichloroBenazamil HCl,
5-tert-butylamino-amiloride,
5-(N-Ethyl-N-isopropyl)amiloride,
(4-Methoxycinnamoyl)guanidine,
4-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,

-187-

(trans-2-Phenylcyclopropanecarbonyl)guanidine,
3-ethoxycinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
4-phenylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(2-Furanacryloyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
5-(N,N-hexamethylene)amiloride,
2,3-difluorocinnamoylguanidine,
2-(1-naphthyl)acetoylguanidine,
(α -Methylcinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
6-Iodoamiloride,
3,4-(methylenedioxy)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
Cinnamoylguanidine,
2-phenylcinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-naphthoylguanidine,
3-phenylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
5-(4-fluorophenyl)amiloride,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
[(4-Chlorophenoxy-acetyl)guanidine,
(3-phenylpropanoyl)guanidine,
2-chloro-6-fluorocinnamoylguanidine,
3-fluorocinnamoylguanidine,
2-methylcinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
1-bromo-2-naphthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
Phenamil methanesulfonate salt,
2,4-dichlorocinnamoylguanidine,
(4-Nitrocinnamoyl)guanidine,
3,4-difluorocinnamoylguanidine and
[(E)-3-(4-Dimethylaminophenyl)-2-methylacryloyl]guanidine.

136. The method according to claim 135, wherein said membrane ion channel is the Hepatitis C virus p7 membrane ion channel.

-188-

137. The method according to any one of claims 118 to 130, wherein said mammal is a primate.
- 5 138. The method according to any one of claims 134 to 136, wherein said mammal is a primate.
139. The method according to claim 137 or claim 138, wherein said primate is human.
- 10 140. The method according to any one of claims 118 to 139, wherein said compound is provided as a pharmaceutical composition according to claim 2 or claim 3.
- 15 141. A method for the therapeutic or prophylactic treatment of a subject infected with or exposed to a virus comprising administering to said subject a compound according to claim 1, wherein said compound down-regulates functional activity of a membrane ion channel derived from said virus.
- 20 142. The method according to claim 141, wherein said virus is a Lentivirus.
143. The method according to claim 142, wherein said Lentivirus is Human Immunodeficiency Virus (HIV).
- 25 144. The method according to claim 143, wherein said membrane ion channel is the HIV Vpu membrane ion channel.
145. The method according to claim 144, wherein said compound is selected from the group consisting of
(3-Chlorocinnamoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
3-(trifluoromethyl)cinnamoylguanidine,

-189-

5-bromo-2-fluorocinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3-dimethylcinnamoylguanidine,
Cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
3,4-dichlorocinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
4-phenylbenzoylguanidine,
2-ethylcinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,,
2-naphthoylguanidine,
2,5-dimethylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-phenylcinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
2-ethoxycinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
(4-Methoxycinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
4-methylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
2-phenylcinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
3-t-butylcinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
3-fluorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-ethoxycinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
2'4 DichloroBenazamil HCl,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
2-(1-naphthyl)acetoyleguanidine,
2,3-difluorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
4-isopropylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,

-190-

N-(cinnamoyl)-N'phenylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-(2-naphthyl)acetoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
N,N'-bis-(cinnamoyl)-N''-phenylguanidine,
(2-Furanacryloyl)guanidine,
Phenamil methanesulfonate salt ,
Benzamil hydrochloride,
(3-Nitrocinnamoyl)guanidine,
Benzyoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2-cyclohexylcinnamoylguanidine,
4-ethoxycinnamoylguanidine,
2,4-dichlorocinnamoylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
N-amidino-3-amino-5-hexamethyleneimino-6-phenyl-
2-pyrazinecarboxamide,
(a-Methylcinnamoyl)guanidine,
cinnamoylguanidine hydrochloride,
[(4-Chlorophenoxy-acetyl]guanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-
pyrazinecarboxamide,
5-(4-fluorophenyl)amiloride,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
trans-3-Furanacryoylguanidine,
1-naphthoylguanidine,
5-tert-butylamino-amiloride,
3-methoxy -HMA,
(3-phenylpropanoyl)guanidine,
4-t-butylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
N,N'-Bis(3-phenylpropanoyl)guanidine,
N-Benzoyl-N'-cinnamoylguanidine and
1-bromo-2-naphthoylguanidine.

146. The method according to any one of claims 143 to 145, wherein said HIV is HIV-1.

5

147. The method according to claim 141, wherein said virus is a Coronavirus.

-191-

148. The method according to claim 147, wherein said membrane ion channel is the Coronavirus E protein.
- 5 149. The method according to claim 148, wherein said Coronavirus is the Severe Acute Respiratory Syndrome virus (SARS).
150. The method according to claim 149, wherein said compound is selected from the group consisting of
- 2,3-difluorocinnamoylguanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 4-t-butylcinnamoylguanidine,
 - 3-(2-naphthyl)acryloylguanidine,
 - (3-Chlorocinnamoyl)guanidine,
 - 3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
 - 2,5-dimethylcinnamoylguanidine,
 - trans-3-(1-naphthyl)acryloylguanidine,
 - 4-isopropylcinnamoylguanidine,
 - (3-Bromocinnamoyl)guanidine,
 - 6-methoxy-2-naphthoylguanidine,
 - 5-(N-Methyl-N-isobutyl)amiloride,
 - 3-phenylcinnamoylguanidine,
 - (2-Chlorocinnamoyl)guanidine,
 - 2'4 DichloroBenazamil HCl,
 - 4-phenylcinnamoylguanidine,
 - 4-(trifluoromethyl)cinnamoylguanidine,
 - 3-(trifluoromethoxy)cinnamoylguanidine,
 - 3-(trifluoromethyl)cinnamoylguanidine,
 - 2-ethoxycinnamoylguanidine,
 - cinnamoylguanidine hydrochloride,
 - 4-ethoxycinnamoylguanidine,
 - (2-Bromocinnamoyl)guanidine,
 - 2,6-dichlorocinnamoylguanidine,
 - 3,4,5-trimethoxycinnamoylguanidine,
 - 5-tert-butylamino-amiloride,
 - 3-t-butylcinnamoylguanidine,
 - 5-bromo-2-fluorocinnamoylguanidine,
 - (4-Chlorocinnamoyl)guanidine,
 - 2-t-butylcinnamoylguanidine,
 - 2-cyclohexylcinnamoylguanidine,
 - 6-Iodoamiloride,
 - 3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
 - (4-Bromocinnamoyl)guanidine,
 - (4-Hydroxycinnamoyl)guanidine,

-192-

N-(3-phenylpropanoyl)-N'-phenylguanidine,
(3-Nitrocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
2-(1-naphthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-naphthoylguanidine,
5-(4-fluorophenyl)amiloride,
2-(trifluoromethyl)cinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
1-naphthoylguanidine,
Benzamil hydrochloride,
3-methoxy -HMA,
4-methylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
N-(cinnamoyl)-N'phenylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Furanacryloyl)guanidine,
(3-phenylpropanoyl)guanidine,
2-(2-naphthyl)acetoylguanidine,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
4-phenylbenzoylguanidine,
2,4-dichlorocinnamolyguanidine,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(Quinoline-2-carbonyl)guanidine,
(Phenylacetyl)guanidine,
N,N'-Bis(amidino)napthalene-2,6-dicarboxamide,
6-bromo-2-naphthoylguanidine,
1-bromo-2-naphthoylguanidine,
2-chloro-6-fluorocinnamoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
Phenamil methanesulfonate salt ,

-193-

N-Benzoyl-N'-cinnamoylguanidine and
N-(2-naphthoyl)-N'-phenylguanidine.

151. The method according to claim 148, wherein said Coronavirus is human Coronavirus 229E.

5

152. The method according to claim 151, wherein said compound is selected from the group consisting of

4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
3-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
2,3-difluorocinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
2-phenylcinnamoylguanidine,
3-phenylcinnamoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
4-phenylbenzoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
4-(trifluoromethyl)cinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
1-naphthoylguanidine,
5-(4-fluorophenyl)amiloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(4-Chlorocinnamoyl)guanidine,
(3-Methoxycinnamoyl)guanidine,
5-bromo-2-fluorocinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,

-194-

(α -Methylcinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,4,6-trimethylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(1-naphthyl)acetoyleguanidine,
2-ethylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
2-ethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
3-fluorocinnamoylguanidine,
cinnamoylguanidine hydrochloride,
2,3-dimethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-tert-butylamino-amiloride,
2-naphthoylguanidine,
N,N'-Bis(amidino)naphthalene-2,6-dicarboxamide,
N,N'-Bis(3-phenylpropanoyl)guanidine,
4-methylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
2,3,5,6-tetramethylcinnamoylguanidine,
3-ethoxycinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N"-phenylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(2-naphthyl)acetoyleguanidine and
N-(3-phenylpropanoyl)-N'-phenylguanidine.

153. The method according to claim 148, wherein said Coronavirus is any one of the known Coronavirus isolates listed in Table 1.

5 154. The method according to claim 153, wherein said compound is selected from the group consisting of
4-isopropylcinnamoylguanidine,

-195-

- 3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
155. The method according to claim 141, wherein said virus is the Hepatitis C virus.
- 5 156. The method according to claim 155, wherein said membrane ion channel is the Hepatitis C virus p7 membrane ion channel.
157. The method according to claim 156, wherein said compound is selected from the group consisting of
- 2,3-dimethylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(2-Chlorocinnamoyl)guanidine,
(4-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3,4-dichlorocinnamoylguanidine,
4-isopropylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
4-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
2-ethylcinnamoylguanidine,
4-methylcinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
1-naphthoylguanidine,
3-t-butylcinnamoylguanidine,
4-phenylbenzoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
N-(cinnamoyl)-N'-phenylguanidine,

-196-

3-isopropylcinnamoylguanidine hydrochloride,
Benzamil hydrochloride,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
3-(2-naphthyl)acryloylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2'4 DichloroBenazamil HCl,
5-tert-butylamino-amiloride,
5-(N-Ethyl-N-isopropyl)amiloride,
(4-Methoxycinnamoyl)guanidine,
4-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
3-ethoxycinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
4-phenylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(2-Furanacryloyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
5-(N,N-hexamethylene)amiloride,
2,3-difluorocinnamoylguanidine,
2-(1-naphthyl)acetoyleguanidine,
(a-Methylcinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
6-Iodoamiloride,
3,4-(methylenedioxy)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
Cinnamoylguanidine,
2-phenylcinnamoylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,
2-naphthoylguanidine,
3-phenylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
5-(4-fluorophenyl)amiloride,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
(3-phenylpropanoyl)guanidine,
2-chloro-6-fluorocinnamoylguanidine,
3-fluorocinnamoylguanidine,
2-methylcinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
1-bromo-2-naphthoylguanidine,

-197-

3,4,5-trimethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
Phenamil methanesulfonate salt,
2,4-dichlorocinnamoylguanidine,
(4-Nitrocinnamoyl)guanidine,
3,4-difluorocinnamoylguanidine and
[(E)-3-(4-Dimethylaminophenyl)-2-
methylacryloyl]guanidine.

158. The method according to any one of claims 141 to 152, wherein said mammal is a primate.
- 5 159. The method according to any one of claims 155 to 157, wherein said mammal is a primate.
160. The method according to claim 158 or claim 159, wherein said primate is human.
- 10 161. An antiviral compound selected from the group consisting of
N-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-N'-phenyl-guanidine,
5-(N-methyl-N-guanidinocarbonyl-methyl)amiloride,
5-(N-Methyl-N-isobutyl)amiloride,
15 5-(N-Ethyl-N-isopropyl)amiloride,
5-(N,N-Dimethyl)amiloride hydrochloride,
5-(N,N-hexamethylene)amiloride,
5-(N,N-Diethyl)amiloride hydrochloride,
3-hydroxy-5-hexamethyleneimino-amiloride,
20 5-(4-fluorophenyl)amiloride,
5-tert-butylamino-amiloride,
N-amidino-3-amino-5-phenyl-6-chloro-2-pyrazinecarboxamide,
3-methoxy-5-(N,N-Hexamethylene)-amiloride,
3-methoxy-amiloride,
25 hexamethyleneimino-6-phenyl-2-pyrazinecarboximide,
N-amidino-3,5-diamino-6-phenyl-2-pyrazinecarboxamide,

-198-

- 1-naphthoylguanidine,
2-naphthoylguanidine,
N-(2-naphthoyl)-N'-phenylguanidine,
N,N'-bis(2-naphthoyl)guanidine,
5 N,N'-bis(1-naphthoyl)guanidine,
N,N'-bis(2-naphthoyl)-N''-phenylguanidine,
6-methoxy-2-naphthoylguanidine,
3-quinolinoylguanidine,
cinnamoylguanidine,
10 4-phenylbenzoylguanidine,
N-(cinnamoyl)-N'phenylguanidine,
(3-phenylpropanoyl)guanidine,
N,N'-bis-(cinnamoyl)-N''-phenylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
15 N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
trans-3-furanacryoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(4-Phenoxybenzoyl)guanidine,
N,N'-Bis(amidino)napthalene-2,6-dicarboxamide,
20 N''-Cinnamoyl-N,N'-diphenylguanidine,
(Phenylacetyl)guanidine,
N,N'-Bis(3-phenylpropanoyl)guanidine,
benzyoylguanidine,
(4-Chlorophenoxy-acetyl]guanidine,
25 N-benzoyl-N'-cinnamoylguanidine,
[(E)-3-(4-Dimethylaminophenyl)-2-methylacryloyl]guanidine,
(4-Chlorocinnamoyl)guanidine,
(4-Bromocinnamoyl)guanidine,
(4-Methoxycinnamoyl)guanidine,
30 (5-Phenyl-penta-2,4-dienoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
(3-Methoxycinnamoyl)guanidine,

-199-

(3-Chlorocinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
(2-Methoxycinnamoyl)guanidine,
5 (trans-2-Phenylcyclopropanecarbonyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
(4-Hydroxycinnamoyl)guanidine,
(Quinoline-2-carbonyl)guanidine,
or pharmaceutically acceptable salts thereof.

10

162. A pharmaceutical composition comprising a compound according to claim 161, and optionally one or more pharmaceutical acceptable carriers or derivatives.

15

163. The pharmaceutical composition according to claim 162, further comprising one or more known antiviral compounds.

20

164. The method according to any one of claims 4 - 6, 10, 11, 14, 17, 19, 21, 23, 25, 27, 29, 30 to 32, 35 to 37, 40, 43, 45, 47, 49, 51, 53, 55, 56 to 58, 61 to 63, 66, 69, 71, 73, 75, 77, 79, 81 to 85, 87 to 89, 92 to 94, 96, 97, 99, 100, 101 to 103, 105 to 108, 110 to 112, 114, 115, 117, 118-120, 122-125, 127-129, 130-131, 133, 134, 136-144, 146-149, 151, 153, 155, or 156, wherein said compound is selected from the antiviral compounds according to claim 161.

25

165. The method according to any one of claims 4, 29, 56, 82, 100 or 142, wherein said virus is Dengue virus and said compound is selected from the group consisting of cinnamoylguanidine, (2-chlorocinnamoyl)guanidine or trans-3-(1-naphthyl)acryloylguanidine.

30

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.